Format

Send to

Choose Destination
Cancer Res. 2019 Feb 15;79(4):853-863. doi: 10.1158/0008-5472.CAN-18-2634. Epub 2018 Nov 6.

Assessment of Tumor Redox Status through (S)-4-(3-[18F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc - Activity.

Author information

1
Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom.
2
Institute of Nuclear Medicine and Department of Chemistry, University College London, London, United Kingdom.
3
Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
4
Department of Radiology, Molecular Imaging Program, Stanford University, Palo Alto, Stanford, California.
5
Life Molecular Imaging GmbH, Berlin, Germany.
6
Department of Bioengineering, Department of Materials Science and Engineering, Bio-X, Stanford University, Palo Alto, Stanford, California.
7
Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom. tim.witney@kcl.ac.uk.

Abstract

: The cell's endogenous antioxidant system is vital to maintenance of redox homeostasis. Despite its central role in normal and pathophysiology, no noninvasive tools exist to measure this system in patients. The cystine/glutamate antiporter system xc - maintains the balance between intracellular reactive oxygen species and antioxidant production through the provision of cystine, a key precursor in glutathione biosynthesis. Here, we show that tumor cell retention of a system xc --specific PET radiotracer, (S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG), decreases in proportion to levels of oxidative stress following treatment with a range of redox-active compounds. The decrease in [18F]FSPG retention correlated with a depletion of intracellular cystine resulting from increased de novo glutathione biosynthesis, shown through [U-13C6, U-15N2]cystine isotopic tracing. In vivo, treatment with the chemotherapeutic doxorubicin decreased [18F]FSPG tumor uptake in a mouse model of ovarian cancer, coinciding with markers of oxidative stress but preceding tumor shrinkage and decreased glucose utilization. Having already been used in pilot clinical trials, [18F]FSPG PET could be rapidly translated to the clinic as an early redox indicator of tumor response to treatment. SIGNIFICANCE: [18F]FSPG PET imaging provides a sensitive noninvasive measure of tumor redox status and provides an early marker of tumor response to therapy.See related commentary by Lee et al., p. 701.

PMID:
30401715
PMCID:
PMC6379064
[Available on 2019-08-15]
DOI:
10.1158/0008-5472.CAN-18-2634

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center